Clinical Trial

Retrospective Identification of Scintigraphic Cardiac Amyloidosis (RISCA)

Study acronym: RISCA
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to determine the positive predictive value of incidental cardiac uptake on bone scintigraphy for diagnosing transthyretin cardiac amyloidosis, in patients who underwent scintigraphy for reasons other than suspected amyloidosis. The study is an observational, descriptive, multicenter, national study using retrospective data from routine care. Patients with incidental cardiac uptake will be recalled for further diagnostic assessment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-03.
Trial Details
NCT Number NCT06921408
Lead Sponsor University Hospital, Lille
Collaborators: Pfizer
Conditions Cardiac Amyloidosis, Transthyretin Amyloidosis
Enrollment 57 participants
Start Date 2026-09-01
Primary Completion 2027-07-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-15